BioAtla (BCAB) Competitors $0.36 0.00 (-0.06%) Closing price 04:00 PM EasternExtended Trading$0.37 +0.01 (+3.37%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ATRA, ABOS, ANRO, ORMP, IVVD, VXRT, CELU, ELUT, BYSI, and EXOZShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Atara Biotherapeutics (ATRA), Acumen Pharmaceuticals (ABOS), Alto Neuroscience (ANRO), Oramed Pharmaceuticals (ORMP), Invivyd (IVVD), Vaxart (VXRT), Celularity (CELU), Elutia (ELUT), BeyondSpring (BYSI), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Atara Biotherapeutics Acumen Pharmaceuticals Alto Neuroscience Oramed Pharmaceuticals Invivyd Vaxart Celularity Elutia BeyondSpring eXoZymes Atara Biotherapeutics (NASDAQ:ATRA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Is ATRA or BCAB more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to BioAtla's net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics3.07% -8.34% 6.61% BioAtla N/A -1,177.18%-137.51% Does the media favor ATRA or BCAB? In the previous week, Atara Biotherapeutics had 13 more articles in the media than BioAtla. MarketBeat recorded 14 mentions for Atara Biotherapeutics and 1 mentions for BioAtla. Atara Biotherapeutics' average media sentiment score of 1.39 beat BioAtla's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, ATRA or BCAB? BioAtla has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.67-$85.40M-$0.43-28.47BioAtla$11M1.90-$69.78M-$1.10-0.32 Do insiders and institutionals have more ownership in ATRA or BCAB? 70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 4.0% of Atara Biotherapeutics shares are held by insiders. Comparatively, 11.2% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate ATRA or BCAB? Atara Biotherapeutics presently has a consensus target price of $21.00, indicating a potential upside of 71.57%. BioAtla has a consensus target price of $5.00, indicating a potential upside of 1,304.49%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80BioAtla 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, ATRA or BCAB? Atara Biotherapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. SummaryAtara Biotherapeutics beats BioAtla on 10 of the 16 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.92M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E RatioN/A20.9030.1925.84Price / Sales1.90390.30474.98187.82Price / CashN/A43.2325.7828.79Price / Book1.429.649.425.99Net Income-$69.78M-$54.08M$3.27B$265.29M7 Day Performance-8.39%2.62%2.05%2.53%1 Month Performance0.34%4.05%3.58%0.92%1 Year Performance-81.16%9.48%30.09%18.70% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla1.9642 of 5 stars$0.36-0.1%$5.00+1,304.5%-81.2%$20.92M$11M0.0060ATRAAtara Biotherapeutics4.6451 of 5 stars$11.48-6.6%$21.00+82.9%+72.8%$86.31M$128.94M-26.70330Positive NewsABOSAcumen Pharmaceuticals3.0463 of 5 stars$1.43+0.7%$6.33+342.9%-47.4%$86.01MN/A-0.6320News CoverageAnalyst ForecastANROAlto Neuroscience1.6729 of 5 stars$3.40+8.4%$8.50+149.7%-65.8%$85.02MN/A-1.42N/AGap DownHigh Trading VolumeORMPOramed Pharmaceuticals0.8224 of 5 stars$2.08flatN/A-13.7%$84.96M$1.34M-5.9410IVVDInvivyd4.1901 of 5 stars$0.58-18.0%$3.85+563.8%-48.5%$84.82M$25.38M-0.63100Analyst ForecastGap UpHigh Trading VolumeVXRTVaxart2.0877 of 5 stars$0.36-0.4%$2.00+448.5%-63.4%$83.47M$47.40M-1.35120Gap DownCELUCelularity0.6916 of 5 stars$4.15+19.3%$6.00+44.6%+19.9%$83.34M$54.22M-1.57220Analyst UpgradeELUTElutia3.6666 of 5 stars$2.02flat$8.00+296.0%-48.1%$83.05M$23.68M-1.91180Gap UpBYSIBeyondSpringN/A$1.85-8.4%N/A-8.3%$81.47M$1.75M0.0080Gap UpHigh Trading VolumeEXOZeXoZymesN/A$9.76+0.6%N/AN/A$81.36M$70K0.0029News CoveragePositive NewsGap Up Related Companies and Tools Related Companies ATRA Alternatives ABOS Alternatives ANRO Alternatives ORMP Alternatives IVVD Alternatives VXRT Alternatives CELU Alternatives ELUT Alternatives BYSI Alternatives EXOZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access